JANX Stock Overview
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer.
Janux Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$13.54|
|52 Week High||US$29.51|
|52 Week Low||US$9.39|
|1 Month Change||21.87%|
|3 Month Change||14.75%|
|1 Year Change||-39.45%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-46.16%|
Recent News & Updates
Janux Therapeutics GAAP EPS of -$0.41, revenue of $2.37M
Janux Therapeutics press release (NASDAQ:JANX): Q2 GAAP EPS of -$0.41. Collaboration Revenue of $2.37M. The company had $354.3 million in cash and cash equivalents and short-term investments at end of second quarter 2022
|JANX||US Biotechs||US Market|
Return vs Industry: JANX underperformed the US Biotechs industry which returned -25.6% over the past year.
Return vs Market: JANX underperformed the US Market which returned -23.2% over the past year.
|JANX Average Weekly Movement||12.6%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: JANX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: JANX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company’s lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells.
Janux Therapeutics Fundamentals Summary
|JANX fundamental statistics|
Is JANX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|JANX income statement (TTM)|
|Cost of Revenue||US$43.85m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.31|
|Net Profit Margin||-809.63%|
How did JANX perform over the long term?See historical performance and comparison
Is JANX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for JANX?
Other financial metrics that can be useful for relative valuation.
|What is JANX's n/a Ratio?|
Price to Book Ratio vs Peers
How does JANX's PB Ratio compare to its peers?
|JANX PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
TSVT 2seventy bio
STOK Stoke Therapeutics
KNTE Kinnate Biopharma
GTHX G1 Therapeutics
JANX Janux Therapeutics
Price-To-Book vs Peers: JANX is good value based on its Price-To-Book Ratio (1.6x) compared to the peer average (3.4x).
Price to Earnings Ratio vs Industry
How does JANX's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book vs Industry: JANX is expensive based on its Price-To-Book Ratio (1.6x) compared to the US Biotechs industry average (1.6x)
Price to Book Ratio vs Fair Ratio
What is JANX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||1.6x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate JANX's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of JANX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate JANX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate JANX's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
How is Janux Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: JANX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: JANX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: JANX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: JANX's revenue (18.5% per year) is forecast to grow faster than the US market (7.7% per year).
High Growth Revenue: JANX's revenue (18.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if JANX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Janux Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Last years earnings growth
Earnings and Revenue History
Quality Earnings: JANX is currently unprofitable.
Growing Profit Margin: JANX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if JANX's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare JANX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: JANX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).
Return on Equity
High ROE: JANX has a negative Return on Equity (-15.85%), as it is currently unprofitable.
Discover strong past performing companies
How is Janux Therapeutics's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: JANX's short term assets ($358.1M) exceed its short term liabilities ($13.0M).
Long Term Liabilities: JANX's short term assets ($358.1M) exceed its long term liabilities ($28.6M).
Debt to Equity History and Analysis
Debt Level: JANX is debt free.
Reducing Debt: JANX had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: JANX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: JANX has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 102.7% each year
Discover healthy companies
What is Janux Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Janux Therapeutics Dividend Yield vs Market|
|Company (Janux Therapeutics)||n/a|
|Market Bottom 25% (US)||1.7%|
|Market Top 25% (US)||4.7%|
|Industry Average (Biotechs)||2.8%|
|Analyst forecast in 3 Years (Janux Therapeutics)||0%|
Notable Dividend: Unable to evaluate JANX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate JANX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if JANX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if JANX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as JANX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
David Campbell (62 yo)
Dr. David Campbell, Ph D serves as President, Chief Executive Officer and Director of Janux Therapeutics, Inc. since inception in June 2017. He founded Janux in 2017 to develop tumor-specific cancer therap...
CEO Compensation Analysis
|David Campbell's Compensation vs Janux Therapeutics Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||US$8m||US$459k|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||US$812k||US$405k|
Compensation vs Market: David's total compensation ($USD8.41M) is above average for companies of similar size in the US market ($USD2.94M).
Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.
Experienced Management: JANX's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Experienced Board: JANX's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|29 Dec 21||SellUS$820,120||OrbiMed Advisors LLC||Company||40,400||US$20.30|
|21 Dec 21||SellUS$2,268,600||OrbiMed Advisors LLC||Company||119,400||US$19.00|
|16 Dec 21||SellUS$7,500,231||OrbiMed Advisors LLC||Company||393,300||US$19.07|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Janux Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: Janux Therapeutics, Inc.
- Ticker: JANX
- Exchange: NasdaqGM
- Founded: 2017
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$561.927m
- Shares outstanding: 41.50m
- Website: https://www.januxrx.com
Number of Employees
- Janux Therapeutics, Inc.
- 11099 North Torrey Pines Road
- Suite 290
- La Jolla
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|JANX||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Jun 2021|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/01 00:00|
|End of Day Share Price||2022/09/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.